Oxidant generation is part of the normal metabolism of many cell types and is critical for homeostasis. Humans have evolved an antioxidant system to protect against oxidative stress---a state of imbalance between oxidant production and antioxidant defenses. Inhaled toxicants such as air pollutants and tobacco smoke can increase oxidative stress ([@b25-ehp0115-001732]; [@b31-ehp0115-001732]; [@b47-ehp0115-001732]) through direct generation of reactive oxygen species (ROS) and through activation of inflammatory leukocytes. Inflammatory cells respond with the "respiratory burst" that involves the uptake of oxygen and release of ROS into the cellular surroundings. Inhaled air pollutants such as ozone interact directly with biomolecules in the respiratory tract lining fluid (RTLF), including unsaturated lipids, nucleic acids, and proteins ([@b34-ehp0115-001732]), damage that is reflected in peripheral blood.

Lipid peroxidation occurs when lipids are attacked by free radical species and hydrogen atoms are extracted from the methylene carbon side chain, initiating a cascade of free ROS that can cause oxidative damage to cell structures ([@b33-ehp0115-001732]; [@b42-ehp0115-001732]). To terminate these events, radicals need to react with each other to create a nonradical species or be quenched by an antioxidant ([@b15-ehp0115-001732]). This secondary inflammatory cell response to the initial oxidative damage results in F~2~-isoprostanes formation, which may contribute to lung injury.

F~2~-isoprostanes are a recently discovered series of bioactive prostaglandin F~2~-like compounds produced independently of the cyclooxygenase enzymes via arachadonic acid (AA) peroxidation ([@b32-ehp0115-001732]). A substantial portion of isoprostanes undergoes β-oxidation in tissues before their release into plasma. Of these, mainly 8-iso-prostaglandins-F~2α~(8-iso-PGF) are formed continuously under normal physiological conditions and can be found at elevated levels as a result of environmental exposures, including O~3~ and cigarette smoke ([@b9-ehp0115-001732]; [@b28-ehp0115-001732]; [@b37-ehp0115-001732]). Chamber studies have shown increased levels of 8-iso-PGF after 1 hr ([@b12-ehp0115-001732]; [@b17-ehp0115-001732]) and 4 hr of exposure to O~3~ in healthy subjects ([@b29-ehp0115-001732]). A recent study found increased plasma levels of 8-iso-PGF in both smokers and nonsmokers after multiday exposure to tobacco smoke ([@b1-ehp0115-001732]), an observation that suggests that chronic exposure may increase oxidative stress.

Clinical studies have shown that in addition to the peroxidation of AA, 8-iso-PGF also reflects the redox status of the microenvironment ([@b24-ehp0115-001732]). 8-iso-PGF and other indicators of redox status have been used as markers of asthma severity ([@b35-ehp0115-001732]) and chronic obstructive pulmonary disease (COPD) ([@b36-ehp0115-001732]; [@b44-ehp0115-001732]). Redox status can serve as an important marker of an individual's response to oxidative stress and is cost-effective to analyze in large epidemiologic studies.

Overall antioxidant capacity is a potential modifying factor of an individual's response to oxidative stress. One such marker is the ferric reducing ability of plasma (FRAP) assay ([@b3-ehp0115-001732]) in which a ferric-to-ferrous ion reduction at low pH causes a colored ferrous--tripyridyltriazine (TPTZ) complex to form. Absorbance changes are linear over a wide concentration range in antioxidant mixtures, including plasma. The FRAP assay has been used in studies on effects of pesticide exposure ([@b45-ehp0115-001732]) and vitamin supplementation on cardiovascular health ([@b7-ehp0115-001732]).

Chronic airway diseases \[e.g., asthma and COPD ([@b43-ehp0115-001732])\] and systemic diseases \[e.g., atherosclerosis and diabetes mellitus ([@b20-ehp0115-001732]; [@b38-ehp0115-001732])\] are associated with increased oxidative stress and lipid peroxidation.

In the present study we explore the association between O~3~ exposure and markers of lipid peroxidation and antioxidant capacity in healthy students from the University of California, Berkeley (UCB), who experienced different seasonal and geographic levels of O~3~ over their lifetimes and during recent summer vacation in either greater Los Angeles (LA) or the San Francisco Bay Area (SF), or were acutely exposed to O~3~ in a controlled environment. This is an extension of a larger project examining the effect of lifetime O~3~ exposure on lung function in young adults ([@b48-ehp0115-001732]).

Materials and Methods
=====================

Study participants and sample collection
----------------------------------------

The overall design of the study, presented in detail by [@b48-ehp0115-001732], included 255 first-year undergraduates at UCB, who were recruited for enrollment over a 2-year period. In this biomarker study, we used a subcohort of participants (*n* = 120) enrolled between February and the first week of June 2002, each of whom provided blood samples ([Table 1](#t1-ehp0115-001732){ref-type="table"}). Eligibility was based on the following: *a*) lifelong residence in either LA or SF, *b*) lifetime never smoker, and *c*) no history of chronic respiratory disease. The majority of participants were Asian (50%) or Caucasian (35%). Hispanics (*n* = 10), African Americans (*n* = 1), and subjects with other ethnic backgrounds (*n* = 7) were pooled together as "Others" for statistical analysis. Lifetime residents of SF composed 51% of the subjects; 56.6% of all subjects were females. By design, ages ranged from 18 to 22 years. During the first 8--12 days of each subject's return to UCB from summertime residences in LA or SF (August--early September 2002), a trained phlebotomist collected small samples of peripheral blood. Plasma was separated from red blood cells and stored in aliquots at −80°C until use. Spirometry was performed as previously described ([@b48-ehp0115-001732]) and included lung function measures of forced expiratory volume in 1 sec (FEV~1~), forced expiratory flow rate between 25 and 75% (FEF~25--75~), forced expiratory flow rate at 75% (FEF~75~), and forced vital capacity (FVC). We also obtained a complete history of summertime (June--August) residences.

Exposure assessment
-------------------

The details for the assessment of lifetime exposure to O~3~ have been described previously ([@b22-ehp0115-001732]; [@b48-ehp0115-001732]). We reconstructed lifetime residential history with a standardized questionnaire; air pollutant \[O~3~, particulate matter with an aerodynamic diameter of ≤10 μm (PM~10~), and nitrogen dioxide (NO~2~)\] concentrations were assigned for each month of life to each residential location. Air quality data were acquired from the California Air Resources Board (ARB, compact disc no. PTSD-02-017-CD), the Aerometric Information Retrieval System, and from special requests to ARB. We interpolated monthly mean measures of O~3~ spatially from air quality monitoring stations to the residence locations with inverse distance weighting and a maximum of three monitoring stations for each interpolation (maximum interpolation radius of 50 km). Lifelong residents of LA had significantly higher estimated lifetime O~3~ exposure than SF residents ([Table 1](#t1-ehp0115-001732){ref-type="table"}). Based on the same interpolation methods, we calculated estimates of short-term exposure to O~3~ based on the moving averages of 8-hr maximum O~3~ concentrations 1--30 days prior to the day of blood collection. Although both 1- and 8-hr maximum O~3~ average levels in LA (0.12 and 0.10 ppm, respectively) during summer were almost double those of SF (0.07 and 0.05 ppm, respectively), individual exposures from up to 1 month before blood collection from subjects in this study overlapped significantly ([Table 1](#t1-ehp0115-001732){ref-type="table"}).

Controlled O~3~ exposure substudy
---------------------------------

The design of this substudy has been described previously ([@b8-ehp0115-001732]). Briefly, we collected peripheral blood from 15 volunteers from the main cohort before and 18 hr after 4 hr of exposure to 200 ppb O~3~ in a chamber with intermittent exercise (30 min of each hour). Four subjects also donated blood immediately after exposure. We conducted chamber studies during the spring when ambient exposures are relatively low and when all study participants had been in SF for several months. Nine of the 15 subjects grew up in SF.

The Committee of the Protection of Human Subjects, UCB, and the Committee on Human Research, University of California, San Francisco, approved all protocols for this study, and we obtained written informed consent from all subjects.

8-Iso-PGF and FRAP assays validation and quality assurance
----------------------------------------------------------

We conducted several pilot experiments prior to the study. The precision of both the 8-iso-PGF and FRAP assays, expressed as the coefficient of variation (CV% = (SD ÷ mean) ×100), was determined from triplicate assays of repeated samples from five laboratory controls with characteristics similar to those of the main study population. Separate plates were analyzed, and the CV% for the same control sample across several experiments fell below 10% for 8-iso-PGF and below 7% for FRAP. We performed additional quality assurance/ quality control (QA/QC) studies to determine if any artifactual formation of 8-iso-PGF levels in plasma could result from sample processing and storage. We compared four conditions for biological processing over a 7-day period: *a*) storage at −80°C after separation of plasma from red blood cells immediately after blood draw; *b*) storage at −20°C immediately; *c*) blood samples left at room temperature 5 hr, then at −80°C for the remainder of 7 days; and *d*) storage at −4°C for 5 hr, then at −80°C, mimicking the biological sample processing condition for this study. All conditions showed similar results with good reproducibility. Results of storage over the 2-week pilot study were comparable with those stored for several months and those reported in previously published studies. All samples, internal positive controls, and randomly distributed blanks were run in triplicate (variability \< 3%, 8-iso-PGF, and \< 5%, FRAP).

8-Iso-PGF assay
---------------

Lipid peroxidation was measured by a competitive enzyme-linked immunosorbent assay (ELISA) for 8-iso-PGF with a commercial kit (Cayman Chemical, Ann Arbor, MI). To prevent cross-reactivity, we purified plasma samples by affinity sorbent chromatography columns in accordance with the manufacturer's protocol. The assay is based on the competition between 8-iso-PGF and 8-isoprostane--acetylcholinestase (AChE) conjugate for a limited number of binding sites in each ELISA plate well. The concentration of 8-iso-PGF is inversely proportional to the number of binding sites available, whereas AChE is held constant. Samples were applied to the column followed by several washes. The last wash that contained purified 8-iso-PGF in the eluate was dried by vacuum centrifugation. We reconstituted the resulting pellet in phosphate buffer (Cayman Chemical, Ann Arbor, MI) and transferred to the ELISA plate. The absorbance of the colorimetric enzymatic reaction was read at 405 nm using the SpectraMax Plus microplate reader (MDS Analytical Technologies, Sunnyvale, CA) and compared with an 8-iso-PGF standard curve to calculate concentration.

FRAP assay
----------

Antioxidant capacity was measured with the FRAP assay ([@b3-ehp0115-001732]). Nonhemolyzed plasma samples were selected and analyzed in triplicate. Color change in the biological sample, measured at 593 nm wavelength 4 min after adding the FRAP reagent (acetate buffer, TPTZ, FeCl~3~ · H~2~O), is directly proportional to the combined reducing power of the antioxidants in the reaction mixture. Samples were run against internal antioxidant standards (α-tocopherol, Fe(II), uric acid, [L]{.smallcaps}-ascorbic acid). The analysis was performed in a 96-well plate with the SpectraMax Plus microplate reader.

Statistical analysis
--------------------

We performed statistical analysis with SAS 9.1 software (SAS Institute Inc., Cary, NC). FRAP levels were distributed normally; 8-iso-PGF levels were log-transformed to normalize the distribution. Student *t*-test was used to determine log 8-iso-PGF and FRAP differences by sex and geographic location. The nonparametric Wilcoxon signed-rank tests for 8-iso-PGF levels yielded the same results as the *t*-tests (results not shown). We used analysis of variance (ANOVA) to determine differences between the three ethnicity groups (coded as dummy variables: 0 = Caucasian, 1 = Asian American, 2 = Other). Bivariate analysis and correlations between log 8-iso-PGF, body mass index (BMI), weight, FRAP, and daily exposure to O~3~ up to 30 days before blood collection were determined by Pearson correlation coefficients. Multivariable analyses were conducted after examination of potential effect modifiers. Sex, ethnicity, BMI, FRAP levels, and O~3~ exposure estimates were included if they were statistically significant based on type III sum of squares. We ran models that included weight rather than BMI, but the results did not change significantly. However, because weight and BMI are collinear, we chose to use BMI, as it takes into account both height and weight. We also explored the effect of these biomarkers on lung function multivariable regression based on models that have been optimized previously for this cohort ([@b48-ehp0115-001732]). The effect of age was not adjusted for in these models because of the narrow age range of subjects in the study.

Results
=======

The distributions of the two biomarkers of oxidative stress, 8-iso-PGF and FRAP, in the study population are presented in [Figures 1](#f1-ehp0115-001732){ref-type="fig"} and [2](#f2-ehp0115-001732){ref-type="fig"}. Levels of 8-iso-PGF had wide interindividual variability (range, 17.4--940.7 pg/mL). Subjects from LA who were exposed to twice the level of O~3~ during the summer compared with those spending their summer in SF had, on average, 2-fold higher 8-iso-PGF ([Table 2](#t2-ehp0115-001732){ref-type="table"}, *p* = 0.02, unpaired *t*-test). Levels of 8-iso-PGF did not vary significantly by sex (*p* = 0.81). Comparisons of 8-iso-PGF levels between sexes by the two geographic regions, LA and SF were not significant (*p* = 0.78 and *p* = 0.42 for men and women, respectively). Although there was no significant difference in 8-iso-PGF levels between the two predominant ethnicities, Caucasian and Asians, there was a suggestion that the "Other" ethnic group had increased 8-iso-PGF levels (*p* = 0.07). However, because of the small numbers, no one subgroup of the heterogeneous "Other" group could be identified as responsible for the difference. No correlation was observed between individual 8-iso-PGF and weight (*r* = 0.10, *p* = 0.27) or BMI (*r* = 0.12, *p* = 0.19).

FRAP levels ranged from 637.2 to 1908.9 μmol/mL. In contrast to 8-iso-PGF, FRAP levels did vary by sex ([Figure 2B](#f2-ehp0115-001732){ref-type="fig"}, *p* = 0.002) but not by geographic region ([Figure 1B](#f1-ehp0115-001732){ref-type="fig"}, *p* = 0.52). However, when comparisons between sexes by the two geographic regions were carried out, males had higher levels in both regions (*p* = 0.009 and *p* = 0.003, respectively). FRAP was also significantly correlated with weight (*r* = 0.40, *p* = 0.0002) and marginally correlated with BMI (*r* = 0.19, *p* = 0.09). Ethnicity was not associated with antioxidant capacity ([Table 2](#t2-ehp0115-001732){ref-type="table"}, *p* = 0.32). FRAP levels were not correlated with 8-iso-PGF (*r* = −0.08, *p* = 0.47).

We estimated individual O~3~ exposures for up to 30 days prior to blood collection based on each subject's summer residence and date of return to SF. Level of 8-iso-PGF showed the strongest associations with 2-week \[β = 0.035 (pg/mL)/8-hr ppb O~3~, *p* = 0.007\] and 1-month \[β = 0.031 (pg/mL)/8-hr ppb O~3~, *p* = 0.006\] prior O~3~ exposure estimates, despite significant overlap between the two geographic categories. However, estimated lifetime exposure had the most precise relation with 8-iso-PGF \[β = 0.025 (pg/mL)/ppb O~3~, *p* = 0.0007\]. There is a 17.41-pg/mL (95% CI, 15.43--19.39 pg/mL) increase in 8-iso- PGF for the 17-ppb cumulative lifetime O~3~ exposure difference between LA and SF subjects. Level of FRAP, on the other hand, was not associated with recent O~3~ exposures {2-week \[β = --7.93 (pg/mL)/8-hr ppb O~3~, *p* = 0.95\] and 1-month \[β = 1.69 (pg/mL)/8-hr ppb O~3~, *p* = 0.76\] prior} or lifetime exposure \[β = --2.21 (pg/mL)/ppb O~3~, *p* = 0.45\]. Correlations between the three O~3~ exposure estimates are presented in Supplemental Material, Table 1 (<http://www.ehponline.org/docs/2007/10294/suppl.pdf>).

The relations between biomarkers of oxidative stress and separate O~3~ (2 weeks prior, 1 month prior, estimated lifetime) exposure estimates were explored further with multivariable regression to control for the following covariates: sex, ethnicity, BMI, and FRAP. O~3~ exposure estimates were the strongest predictors for level of 8-iso-PGF ([Table 3](#t3-ehp0115-001732){ref-type="table"}). A final model that included all three exposure metrics further confirmed that each exposure period had an independent association with 8-iso-PGF levels. The covariates did not contribute significantly to any model and their exclusion did not change the magnitude of the associations \[Supplemental Material, Table 2 (online at <http://www.ehponline.org/docs/2007/10294/suppl.pdf>)\].

The contribution of the estimated lifetime O~3~ exposure, independent of the recent 2-week and 1-month O~3~ exposures, was determined by evaluation of the distribution of residuals from a separate regression model that used the two short-term exposures as independent variables and lifetime exposure as the outcome \[Supplemental Material, Table 3 (<http://www.ehponline.org/docs/2007/10294/suppl.pdf>)\]. The lifetime exposure residuals obtained from this model were used as the O~3~ exposure variable in a final multivariable model and confirmed an independent effect of cumulative lifetime exposure \[β = 0.025 (pg/mL)/ppb O~3~, *p* = 0.004\].

Increased FRAP in females was marginally associated with lower lung function, FEF~75~ \[Supplemental Material, Figure 1A; β = −0.0001 (μmol/mL)/(mL/sec), *p* = 0.15\], after the removal of an outlier. In males, however, FRAP levels paralleled FEF~75~, although it was not statistically significant \[Supplemental Material, Figure 1B; β = −0.0001 (μmol/mL)/ (mL/sec), *p* = 0.67\]. No relation between 8-iso- PGF and FEF~75~ was found in either sex \[Supplemental Material, Figure 2 (<http://www.ehponline.org/docs/2007/10294/suppl.pdf>)\].

Biomarker levels from the acute exposure substudy are presented in [Figure 3](#f3-ehp0115-001732){ref-type="fig"}. The levels of 8-iso-PGF increased from 28.5 pg/mL at baseline to 51.1 pg/mL immediately after O~3~ exposure ended (*p* = 0.10) and by 18 hr had returned close to baseline (30.5 pg/mL, [Table 4](#t4-ehp0115-001732){ref-type="table"}). There was a (22%) decrease in FRAP immediately after exposure (*p* = 0.17). Antioxidant capacity returned to near pre-exposure levels by 18 hr (723.5 vs. 771.4 μmol/mL, respectively). Individual FRAP values before and 18 hr after exposure were significantly correlated (*r* = 0.82, *p* \< 0.0001); however, 8-iso-PGF measures were not (*r* = 0.48, *p* = 0.20). Correlations between levels at baseline and 4 hr after exposure, although relatively high, were not statistically significant for either FRAP (*r* = 0.77, *p* = 0.23) or 8-iso-PGF (*r* = 0.71, *p* = 0.23), possibly because of a relatively small number of subjects in the chamber study. Overall, average FRAP and 8-iso-PGF levels were lower in this controlled exposure substudy than in the larger cohort study. However, these same subjects were on the lower end of the isoprostane distribution for the entire study group. Additionally, the acute exposures were all conducted during the spring in SF when ambient pollution levels are low. Furthermore, 9 of the 15 subjects were lifetime SF residents with comparatively less O~3~ exposure than LA subjects.

Discussion
==========

Previously, we demonstrated that estimated lifetime exposure to ambient O~3~ in a cohort of young healthy adults was associated with reduced measures of lung function that reflect the physiology of the small airways, FEF~75~ and FEF~25--75~ ([@b48-ehp0115-001732]). We also found that residence during summer seasons of elevated O~3~ in two geographic regions differentially affected cytogenetic damage in oral epithelia ([@b8-ehp0115-001732]). Subjects who spent the summer in LA had significantly higher micronucleus frequencies than those who stayed in SF. Here, we observed a similar group effect of high oxidant region (summers in LA vs. SF) on elevated lipid peroxidation, as measured by 8-iso-PGF, in the same cohort. Addtionally, we determined if an individual's exposure over varying periods of time affected his/her 8-iso-PGF levels. Multivariable regression demonstrated that estimated 2-week prior, 1-month prior, and lifetime O~3~ exposures of young healthy individuals were significantly and independently associated with increased 8-iso-PGF levels, while controlling for sex and ethnicity. In particular, these findings indicate that long-term exposure to elevated O~3~ can contribute to oxidant burden over periods longer than 1 month. Results from the controlled exposure substudy confirmed that oxidative stress increases after 4 hr of O~3~ exposure. Levels of 8-iso-PGF returned to near baseline by 18 hr without further exposure.

Although free 8-iso-PGF in humans has a relatively short half-life (\~ 16 min), the time course observed in the participants of the acute study mirrored those reported in previous animal models of oxidant stress ([@b30-ehp0115-001732]). In the larger cohort study, we expected an individual's most recent exposure (1- to 7-day time lag) prior to sample collection to correlate best with 8-iso-PGF. Contrary to this expectation, we observed significant effects for slightly longer recent O~3~ exposures (2 weeks and 1 month prior to blood collection) on 8-iso-PGF. Somewhat surprisingly, lifetime exposure also had a significant association with increased levels of this biomarker of lipid peroxidation, possibly because of greater precision for lifetime estimate than that for shorter lag times.

Even though we cannot be certain that the lifetime exposure associated with repeated oxidant injury has led to a chronic state of oxidative stress that persists over many years, the data do indicate chronic exposure of at least 2--4 weeks contributes to subacute oxidative stress. The observed oxidant effects on lipid peroxidation are consistent with those in other studies examining chronic oxidative stress. [@b1-ehp0115-001732] reported that 8-iso-PGF levels increased during passive exposure of nonsmokers to cigarette smoke but tended to return to baseline by 6 hr post-exposure. After repeated exposure over 12 days, however, 8-iso-PGF levels in these nonsmokers rose to levels that approached those of active smokers. These results, together with ours, suggest that repeated exposures to oxidant pollutants can lead to sustained oxidative stress that, in turn, causes increased lipid peroxidation. The only other long-term study of the effect of air pollution on lipid peroxidation found a 30% decrease in the thiobarbituric acid reactive substances (TBARS) assay with extended stay in highly polluted areas of Mexico City ([@b27-ehp0115-001732]). The TBARS assay measures a different lipid peroxidation end point, malondialdehyde, and has been shown to be nonspecific and provide erroneously high estimates ([@b14-ehp0115-001732]; [@b19-ehp0115-001732]).

O~3~ alone also may not be responsible for the associations observed. As we reported previously, in California the O~3~ season does not overlap with that of PM~2.5~ but does coincide with the seasonal rise of PM~10--2.5~ and NO~2~ ([@b48-ehp0115-001732]), and these air pollutants are highly correlated in this study population \[Supplemental Material, Table 4 (<http://www.ehponline.org/docs/2007/10294/suppl.pdf>)\]. Additional multivariable analysis confirmed a significant effect of these co-pollutants; however, their inclusion in the models did not change the magnitude of the associations with O~3~. Furthermore, the validity of the association with ambient O~3~ exposure estimates in our study were strengthened by chamber substudy results, where O~3~-induced 8-iso-PGF was also increased after 4 hr of exposure compared with baseline. Here, the effect of O~3~, is clear and cannot be attributed to other pollutants. These results are consistent with those of other chamber studies that have observed an increase in lipid peroxidation after acute O~3~ exposure ([@b10-ehp0115-001732]; [@b12-ehp0115-001732]; [@b17-ehp0115-001732]; [@b29-ehp0115-001732]).

Our FRAP data showing that subjects living in LA during the summer had decreased antioxidant capacity compared with those who stayed in SF corroborate an earlier study by [@b27-ehp0115-001732]. Their study showed decreased antioxidant status, measured by serum superoxide dismutase, in subjects living in highly polluted areas compared with that in controls. Additionally, we observed a mild suppression of antioxidant levels, as measured by the FRAP assay, in the chamber substudy immediately after 4 hr of exposure to O~3~. Although no other studies have used the FRAP assay to assess the effect of air pollution on antioxidant capacity, β-carotene supplementation has been shown to increase FRAP levels ([@b7-ehp0115-001732]), and exposure to pesticides caused levels to decrease ([@b45-ehp0115-001732]).

We observed broad interindividual variability in both biomarkers of oxidative stress, and explored the role of host factors such as sex, ethnicity, weight, and BMI. We found no significant associations between 8-iso-PGF levels and these covariates in either bivariate or multivariable regression analyses. In contrast, other studies of older adult subjects have reported that females have higher levels of 8-iso-PGF than males ([@b5-ehp0115-001732]; [@b6-ehp0115-001732]; [@b11-ehp0115-001732]). This effect of sex may be due to higher body mass and percentage fat in adult women, as BMI was associated significantly with lipid peroxidation in one study ([@b6-ehp0115-001732]). The women in our population of healthy young students, however, tended to have low BMI levels.

The men in our study had significantly higher antioxidant capacity than females, as measured by FRAP, that could have masked an overall effect of sex on 8-iso-PGF. The role of sex in antioxidant capacity was reported previously in a population of older adults ([@b4-ehp0115-001732]). We observed a moderate correlation between FRAP and BMI (*r* = 0.19, *p* = 0.09) and a significant correlation between FRAP and weight (*r* = 0.40, *p* \< 0.0001). Furthermore, overall antioxidant levels were not significantly correlated with 8-iso-PGF levels. This suggests that an aggregate measure of antioxidant capacity such as FRAP may not be as informative to an individual's lipid peroxidation status in response to O~3~ ([@b33-ehp0115-001732]). However, total antioxidant capacity have been used successfully to characterize disease status in asthma and COPD ([@b35-ehp0115-001732]; [@b44-ehp0115-001732]).

Although O~3~ exposure has been demonstrated to affect lipid peroxidation in this study, another factor that may contribute to interindividual variability is self-reported ethnicity. The majority of subjects were either Caucasian or Asian, which reflects the demographics of the UCB student population. While we observed a marginal effect of race/ ethnicity on 8-iso-PGF ("Others," *p* = 0.07), we acknowledge that self-reported race/ ethnicity is not a precise biological concept ([@b16-ehp0115-001732]; [@b18-ehp0115-001732]; [@b39-ehp0115-001732]; [@b41-ehp0115-001732]). One study reported that African Americans have lower 8\--iso-PGF levels than Caucasians ([@b6-ehp0115-001732]), whereas other studies have not observed any differences among ethnicities ([@b21-ehp0115-001732]; [@b26-ehp0115-001732]). Some of the variability seen in this study may be explained by polymorphisms of genes involved in antioxidant defenses, many of which vary by race/ethnicity. For example, we found that both genotype frequencies and enzyme activity of manganese superoxide dismutase, a polymorphic enzyme involved in antioxidant defense, varied by ethnicity in this same cohort ([@b2-ehp0115-001732]). The effects of such polymorphisms on lipid peroxidation are currently being explored.

The relations between 8-iso-PGF, FRAP, and previously established O~3~-induced cytogenetic damage ([@b8-ehp0115-001732]) and lung function decrements ([@b48-ehp0115-001732]) were also assessed. Lipid peroxidation was not associated with lung function \[Supplemental Material, Figure 2 (online at <http://www.ehponline.org/docs/2007/10294/suppl.pdf>)\] and only marginally associated with cytogenetic damage as assessed by the micronucleus frequency during the fall (*r* = 0.15, *p* = 0.09; Spearman correlation). FRAP was inversely associated with cytogenetic damage (*r* = --0.21, *p* = 0.06) and lung function \[Supplemental Material, Figure 1 (online at <http://www.ehponline.org/docs/2007/10294/suppl.pdf>)\].

The results of both the main chronic study and the chamber substudy presented here provide additional evidence that inhalation of O~3~ causes lipid peroxidation that can be detected in peripheral blood. 8-Iso-PGF appears to be a good biomarker of the oxidative damage related to inhaled O~3~ and high oxidant environments. We have demonstrated an effect of a single controlled O~3~ exposure and chronic ambient exposure on elevated 8-iso-PGF. Additional studies involving single, acute exposures that examine the 8-iso-PGF time course and repeated acute exposures in humans are warranted to elucidate the true effect of chronic exposure and accumulation of 8-iso-PGF over time. The implications of the results presented here are particularly significant because oxidative stress that results from exposure to ambient pollutants may contribute to lung cancer, asthma, and cardiopulmonary morbidity and mortality ([@b13-ehp0115-001732]; [@b23-ehp0115-001732]; [@b40-ehp0115-001732]; [@b46-ehp0115-001732]).

Supplemental Material is available online at <http://www.ehponline.org/docs/2007/10294/suppl.pdf>
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![Boxplot distribution of levels of log-transformed 8-iso-PGF stratified by sex in two groups of students who spent their summer break in two geographic locations, SF (*n* = 61) and LA (*n* = 51). Overall, subjects from LA had significantly higher levels of 8-iso-PGF than those from SF (*p* = 0.02). The box represents the interquartile range; the horizontal line inside the box represents the median; and the vertical lines represent the minimum and maximum values.](ehp0115-001732f1){#f1-ehp0115-001732}

![Boxplot distributions of levels of FRAP by sex in two groups of students who spent their summer break in two geographic locations, LA and SF. Overall, men (*n* = 52) had significantly higher FRAP levels than women (*n* = 68, *p* = 0.002). The box represents the interquartile range; the horizontal line inside the box represents the median; and the vertical lines represent the minimum and maximum values.](ehp0115-001732f2){#f2-ehp0115-001732}

![Distribution of (*A*) 8-iso-PGF and (*B*) FRAP after acute exposure to 200 ppb for 4 hr (*n* = 15). Data are presented as mean ± SD.\
\*Mean value significantly different than other time points.](ehp0115-001732f3){#f3-ehp0115-001732}
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Cohort characteristics.

  Characteristic                                       LA                   SF                   Total
  ---------------------------------------------------- -------------------- -------------------- --------------------
  No. of subjects                                      59                   61                   120
  Sex (% female)                                       56.9                 57.3                 56.6
  Ethnicity (%)                                                                                  
   Caucasian                                           45.8                 54.1                 50
   Asian                                               30.5                 41.0                 35.8
   Other                                               23.7                 4.9                  14.5
  Age (years)                                          19 (19--20)          19 (18--22)          19 (18--22)
  Weight (kg)                                          62.3 (46.8--97.0)    62.5 (40.9--113.9)   62.4 (40.9--113.9)
  BMI                                                  22.4 (17.2--37.4)    21.8 (16.8--32.2)    22.2 (16.8--37.4)
  Recent O~3~ exposures (8-hr moving averages, ppb)                                              
   2 week                                              30.7 (14.3--43.1)    30.9 (13.5--47.9)    30.8 (13.5--47.9)
   1 month                                             28.4 (5.0--41.8)     28.1 (14.1--43.1)    28.3 (5.0--43.1)
  Lifetime exposure (estimated monthly average, ppb)                                             
   O~3~                                                42.9 (28.5--65.3)    26.9 (17.6--33.5)    30.5 (17.6--65.3)
   PM~10~ (before 1987)                                92.0 (63.9--124.2)   52.6 (34.2--89.6)    68.1 (34.2--124.2)
   PM~10~ (after 1987)                                 42.3 (25.7--67.9)    25.6 (17.8--28.6)    28.5 (17.3--67.9)
   NO~2~                                               39.7 (8.3--49.9)     21.6 (11.4--29.6)    26.9 (8.3--49.9)

Data are presented as either percentage or median (range).

###### 

Biomarkers of lipid peroxidation (8-iso-PGF) and antioxidant capacity (FRAP).

  Parameter               8-Iso-PGF[a](#tfn2-ehp0115-001732){ref-type="table-fn"},[b](#tfn3-ehp0115-001732){ref-type="table-fn"}   FRAP[a](#tfn2-ehp0115-001732){ref-type="table-fn"},[c](#tfn4-ehp0115-001732){ref-type="table-fn"}
  ----------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Geographic location                                                                                                              
   SF (*n* = 59)          97.2 (17.4--674.7)[\*](#tfn5-ehp0115-001732){ref-type="table-fn"}                                        1,059.4 (637.2--1686.0)
   LA (*n* = 61)          195.3 (18.6--940.7)                                                                                      1,002.5 (660.1--1908.9)
  Sex                                                                                                                              
   Male (*n* = 52)        133.1 (17.4--807.2)                                                                                      1,196.3 (637.2--1908.9)[\*](#tfn5-ehp0115-001732){ref-type="table-fn"}
   Female (*n* = 68)      154.9 (18.6--940.7)                                                                                      970.8 (660.1--1429.5)
  Ethnicity                                                                                                                        
   Caucasian (*n* = 42)   126.1 (18.6--940.7)                                                                                      1,041.4 (637.2--1686.0)
   Asian (*n* = 60)       169.4 (14.4--877.5)                                                                                      1,065.5 (685.8--1908.9)
   Other (*n* = 18)       154.1 (34.9--574.1)                                                                                      884.1 (757.5--1686.0)

Data are presented as median (range).

Raw values presented in pg/mL; log--transformed concentrations were used for regression analyses.

Values are μmol/mL.

*p* \< 0.05.

###### 

Exposure models for predictors of 8-iso-PGF in healthy young adults.

             Model                                                                                                                                                                                        
  ---------- -------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------
  2 weeks    0.035 (0.015)[\*](#tfn7-ehp0115-001732){ref-type="table-fn"}                                                                                                                                 0.023 (0.010)[\*](#tfn7-ehp0115-001732){ref-type="table-fn"}
  1 month                                                                   0.031 (0.013)[\*](#tfn7-ehp0115-001732){ref-type="table-fn"}                                                                  0.025 (0.009)[\*](#tfn7-ehp0115-001732){ref-type="table-fn"}
  Lifetime                                                                                                                                 0.024 (0.008)[\*](#tfn7-ehp0115-001732){ref-type="table-fn"}   0.023 (0.006)[\*](#tfn7-ehp0115-001732){ref-type="table-fn"}

Data are presented as coefficient (SE). Outcome of 8-iso-PGF was log-transformed to normalized distribution. Units for parameter estimates are log 8-iso-PGF/change in O3 measure (8-iso-PGF: pg/mL; O~3~ measure: 2 weeks, 1 month = ppb 8-hr maximum; lifetime exposure ppb-hr). Separate models were run for each exposure metric. The full models that include other covariates (sex, BMI, etc.) can be found in Supplemental Material (<http://www.ehponline.org/docs/2007/10294/suppl.pdf>).

*p* \< 0.05.

###### 

8-Iso-PGF and FRAP after acute exposure to 200 O~3~ ppb for 4 hr (*n* = 15).

                      Preexposure     4 hr postexposure[a](#tfn9-ehp0115-001732){ref-type="table-fn"}   18 hr postexposure
  ------------------- --------------- ----------------------------------------------------------------- --------------------
  8-iso-PGF (pg/mL)   28.5 ± 12.5     51.1 ± 25.1[\*](#tfn10-ehp0115-001732){ref-type="table-fn"}       30.5 ± 7.4
  FRAP (μmol/mL)      771.4 ± 234.7   600.3 ± 86.4                                                      723.5 ± 205.8

Data are presented as mean ± SD.

*n* = 4.

*p* \< 0.10, ANOVA (Tukey post hoc) compared with preexposure and 18 hr postexposure.
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